Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma

Clinical Cancer Research

Volumn 11, Issue 3, 2005, Pages 1065-1072

  Banham, Alison H ^a   Connors, Joseph M ^b   Brown, Philip J ^a   Cordell, Jacqueline L ^a   Ott, German ^c   Sreenivasan, Gayatri ^b   Farinha, Pedro ^b   Horsman, Douglas E ^b   Gascoyne, Randy D ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FOXP2; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR FOXP4; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANIMAL CELL; ANTIBODY SPECIFICITY; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE ACTIVATION; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MALE; MULTIVARIATE ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY;

EID: 12944273473     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
2. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001;412:341-6.
3. Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol 2001;13:325-34.
4. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6.
5. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
6. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-47.
7. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74.
8. Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 2003;100:9991-6.
9. Lossos IS, Alizadeh AA, Eisen MB, et al. Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci U S A 2000;97:10209-13.
10. Huang JZ, Sanger WG, Greiner TC, et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002;99:2285-90.
11. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82.
12. Banham AH, Beasley N, Campo E, et al. The FOXP1 winged helix transcription factor is a novel candidate rumor suppressor gene on chromosome 3p. Cancer Res 2001;61:8820-9.
13. Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2002;2:920-32.
14. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning. A laboratory manual. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 1989.
15. Bruce HA Margolis RL. FOXP2: novel exons, splice variants, and CAG repeat length stability. Hum Genet 2002;111:136-44.
16. Erber WN, Pinching AJ, Mason DY. Immunocytochemical detection of T and B cell populations in routine blood smears. Lancet 1984;1:1042-6.
17. Weigel D, Seifert E, Reuter D, et al. Regulatory elements controlling expression of the Drosophila homeotic gene fork head. EMBO J 1990;9:1199-207.
18. Carlsson P, Mahlapuu M. Forkhead transcription factors: key players in development and metabolism. Dev Biol 2002;250:1-23.
19. Lai CS, Fisher S E, Hurst JA, et al. A forkhead-domain gene is mutated in a severe speech and language disorder. Nature 2001;413:519-23.
20. Chatila TA, Blaeser F, Ho N, et al. JM2, encoding a fork head-related protein, is mutated in X-linked auto immunity-allergic disregulation syndrome. J Clin Invest 2000;106:R75-81.
21. Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001;27:20-1.
22. Bennett CL, Brunkow ME, Ramsdell F, et al. A rare polyadenylation signal mutation of the FOXP3 gene (AAUAAA-AAUGAA) leads to the IPEX syndrome. Immunogenetics 2001;53:435-9.
23. Brunkow ME, Jeffery EW, Hjerrild KA, et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001;27:68-73.
24. Wildin RS, Ramsdell F, Peake J, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001;27:18-20.
25. Newbury DF, Bonora E, Lamb JA, et al. FOXP2 is not a major susceptibility gene for autism or specific language impairment. Am J Hum Genet 2002;70:1318-27.
26. Kok K, Naylor SL, Buys CH. Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes. Adv Cancer Res 1997;71:27-92.
27. Johansson B, Billström R, Kristoffersson U, et al. Deletion of chromosome arm 3p in hematologic malignancies. Leukemia 1997;11:1207-13.
28. Barrans SL, Fenton JA, Banham A, et al. Strong expression of FoxPl identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 2004;104:2933-5.